Consistent with this, intraperitoneal administration of the selective HDAC3 inhibitor, RGFP966, protected against BLM-induced pulmonary fibrosis in mice by targeting EMT in AT2 cells. Here, HDAC3 is linked to pulmonary fibrosis.